, and industry to discuss patient-reported outcomes (PROs) and patient preference information (PPI) measures in research, clinical practice, and regulatory decision-making. Many stakeholders and their organizations have advocated for the inclusion of patients' perspectives in clinical care, research, and regulatory decisions. The consensus is that PROs and patient preferences are important and necessary to inform the decisions that are made by healthcare providers, patients, and their families, as well as the information collected by researchers and medical product manufacturers and reviewed by regulators in the development of medical products [1, 2] .
All participants had a stake in the development of safe and effective treatments for Alzheimer, Huntington, and Parkinson diseases. The symposium objectives were to both build new and strengthen existing relationships between patients, family caregivers, researchers, clinicians, pharmaceutical and medical device manufacturers, and regulatory decision-makers, and also to provide a forum in which participants could convene, collaborate, and critically assess areas of unmet need. The symposium included keynote addresses and workshops focused on three topics: (1) ''PROs for Clinical Research and Medical Product Development''; (2) ''PROs for Clinical Care''; and (3) ''Patient Preferences for Risk-Benefit Assessments''.
Karen Anderson, MD (Georgetown University), provided an introduction to the meeting and outlined the mission of the working groups. Plenary sessions were held to provide an overview of topic areas and to flag particular unmet needs. The ''PROs for Clinical Care'' session, co-chaired by Tanya Simuni, MD (Northwestern University), MaryAnne Sterling, a caregiver, and Pierre Tariot, MD (Banner Health), examined the utility and challenges in using PROs to inform patient care by aligning patient, caregiver, and clinician goals and expectations. Within this broad topic, the group identified four categories of unmet needs: communication, access to care, education, and patient/provider partnership. Obstacles to addressing these needs included lack of time, need for privacy and security, and limited financial and geographic access to team care. The discussion generated suggestions for next steps: The ''Patient Preferences Information (PPI) for RiskBenefit Assessments'' session, co-chaired by Telba Irony, PhD (Center for Biologics Evaluation and Research, FDA), Tara LoCastro, MBA, caregiver, and Bernard Ravina, MD (Voyager Therapeutics), examined the application of PPI in assessing the benefits and risks of experimental interventions. The workshop group highlighted prior work that identified the unmet needs for effectively incorporating patient preferences in all stages of research, increased research to characterize patient and caregiver preferences, and effective methods to capture this information. Many barriers to designing patient preference studies became evident from the discussion, including clinicians' or researchers' differing assumptions about patient preferences. One example is the assumption that risk-benefit assessments change over time due to disease progression, increase in cognitive and behavioral impairment, or new information. However, such data have not been systematically collected. Additional barriers to reliability and the longitudinal assessment of risk-benefit patient preference data include product changes, treatment purpose (targeting symptoms vs. disease altering), and the role of emotion and insight in decision-making. Cognitive decline exacerbates challenges to effectively capturing patient preferences, and methods may need to further examine these issues in patients with neurodegenerative disorders. Lastly, smaller companies are at a disadvantage to effectively include patient preferences in clinical research due to their need to limit study development costs, especially in early stages of development. The discussion generated suggestions for next steps:
1. Shift focus from what is wrong with the patient to the patient's priorities by directly asking the patient to judge his or her own healthcare needs. 2. Fund research to incorporate patient perspectives at multiple timepoints during the development lifecycle, including earlier, throughout, and at the end. This will clarify how patient preferences change with disease progression. 3. Require collecting risk-benefit PPI in post-market surveillance if there is uncertainty or the patient population is expected to differ appreciably from the research population. Post-marketing insight is often a missed opportunity to access patient and family member insights and lessons learned.
Working groups presented these summaries at the end of the symposium. Commentary was then provided by Joel Grace, a Parkinson disease patient and advocate, who gave the ''Patient Perspective Closing Remarks''. Ira Shoulson, MD (Georgetown University), summarized the discussion and findings.
The symposium demonstrated the need to increase patient engagement for development of PROs and PPIs in the settings of clinical care, research, and risk-benefit assessments for neurodegenerative diseases. All stakeholders had a vested interest in enhanced patient engagement. The regulators, who make decisions about medical products, benefit from patient information to decide in the best interest of patients. Researchers in academia and innovators in industry, who work together to create and develop treatments, rely on patients and families to volunteer for clinical trials to test investigative treatments and use these treatments once they are FDA approved for marketing. Accordingly, researchers and innovators need to understand and value patient reports and their preferences. Patients and care partners rely on drug developers and clinicians, who create and prescribe treatments. Therefore, patients and care partners stand as eager collaborators to develop better care and treatment.
The symposium highlighted the dearth of existing research in this area, and identified a number of tangible next steps for stakeholders to improve communication between all stakeholders on related issues. While a scarcity of resources presents a challenge, many next steps were suggested to advance PROs and patient preferences in clinical research and medical product development, PROs for clinical care, and PPI for risk-benefit assessments for regulatory decision-making. Future patient-centered symposia and workshops are expected to advance progress for those affected by neurodegenerative diseases.
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